Sanofi’s Berger On Creating A Sleek R&D Engine Fit For Purpose In The 2020s

A change in direction for the French firm means a new approach to R&D. Sanofi’s global head of development and chief medical officer Dietmar Berger talked to In Vivo about what was needed to get the company’s R&D machine back on track. 

Cogs on purple background
• Source: Shutterstock

If you want to make a statement of intent, dropping R&D in an entire therapeutic area for which your company is renowned is guaranteed to work, even when the writing had been on the wall for some time.

Sanofi's decision in 2019 to exit diabetes research was the starkest manifestation of the major changes its new CEO...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo